Global Pidotimod Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pidotimod Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Pidomod (CAS 121808-62-6), also known as primo, spectrum leyi, is an immunomodulator, suitable for patients with low immune function of the body, and can be used to prevent acute infection, shorten the course of disease, reduce the severity of the disease, can be used as an auxiliary drug during the acute infection period.Mainly used in children recurrent respiratory tract infection, urinary tract infection (urinary tract infection), chronic bronchitis also has therapeutic effect, to the virus.Influenza and viral herpes are effective.It can also be used for infection caused by pneumococcal pneumonia and escherichia coli, pseudomonas aeruginosa and proteus.
Pidotimod report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pidotimod market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Gynecological Infection and Urinary Tract Infection (UTI) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pidotimod industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pidotimod key manufacturers include Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical and Dr. Reddy’s, etc. Active Peptide Company, Reco Tech, Manus Aktteva Biopharma are top 3 players and held % sales share in total in 2022.
Pidotimod can be divided into Piece, Oral Liquid, Capsule and Particles, etc. Piece is the mainstream product in the market, accounting for % sales share globally in 2022.
Pidotimod is widely used in various fields, such as Gynecological Infection, Urinary Tract Infection (UTI), Respiratory Infections and Other, etc. Gynecological Infection provides greatest supports to the Pidotimod industry development. In 2022, global % sales of Pidotimod went into Gynecological Infection filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pidotimod market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Active Peptide Company
Reco Tech
Manus Aktteva Biopharma
Joyochem
Changzhou Yinsheng Pharmaceutical
Dr. Reddy’s
Segment by Type
Piece
Oral Liquid
Capsule
Particles
Other
Gynecological Infection
Urinary Tract Infection (UTI)
Respiratory Infections
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pidotimod market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pidotimod, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pidotimod industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Pidotimod in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pidotimod introduction, etc. Pidotimod Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pidotimod market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Pidotimod report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pidotimod market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Gynecological Infection and Urinary Tract Infection (UTI) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pidotimod industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pidotimod key manufacturers include Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical and Dr. Reddy’s, etc. Active Peptide Company, Reco Tech, Manus Aktteva Biopharma are top 3 players and held % sales share in total in 2022.
Pidotimod can be divided into Piece, Oral Liquid, Capsule and Particles, etc. Piece is the mainstream product in the market, accounting for % sales share globally in 2022.
Pidotimod is widely used in various fields, such as Gynecological Infection, Urinary Tract Infection (UTI), Respiratory Infections and Other, etc. Gynecological Infection provides greatest supports to the Pidotimod industry development. In 2022, global % sales of Pidotimod went into Gynecological Infection filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pidotimod market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Active Peptide Company
Reco Tech
Manus Aktteva Biopharma
Joyochem
Changzhou Yinsheng Pharmaceutical
Dr. Reddy’s
Segment by Type
Piece
Oral Liquid
Capsule
Particles
Other
Segment by Application
Gynecological Infection
Urinary Tract Infection (UTI)
Respiratory Infections
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pidotimod market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pidotimod, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pidotimod industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Pidotimod in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pidotimod introduction, etc. Pidotimod Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pidotimod market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices